Global Generic Drugs
Global Generic Drugs

Generic Drugs Comprehensive Study by Type (Simple Generic Drugs, Super Generic Drugs, Biosimilars), Application (Respiratory Products, Anti-Infective Drugs, Central Nervous System Drugs, Cardiovascular Products, Anti-Arthritis Drugs, Anti-Cancer Drugs, Other), Sales Channel (Sales Channel Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Channels), Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers) Players and Region - Global Market Outlook to 2025

Generic Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025 | CAGR: 9.12%  

Aug 2020 Edition 207 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Generic Drugs Market Overview:
Generic Drugs are referred to as a drug product that is comparable to a brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended use. These drugs have the same active ingredients, dosage form, strength, route of administration, and conditions of use as original branded products but with lower prices. Generic drugs help to reduce drug costs and increase drug use. According to the Association for Accessible Medicines, 89% of all prescriptions dispensed in the United States are filled with a generic drug. North America region is the largest supplier of generic drugs, following Europe is the second-largest supplier of generic drugs. Of the Asian countries, India is emerging as a leading country for the generic drugs market. According to AMA, the Global Generic Drugs market is expected to see growth rate of 9.12%

Market Drivers
  • Increasing Demand for Generic Drugs in Emerging Countries such as China and India
  • Cost-Benefit compared to the Branded Drugs
  • Large Number of Patent Expired Branded Drugs

Market Trend
  • Advent of Robotic Process Automation (RPA)

Restraints
  • Stringent Governmental Regulations
  • Adverse Effects Associated With Generic Drugs

Opportunities
  • Government Promoting the Pharmaceutical Sector
  • Increasing Use of Hospital-owned Generics

Challenges
  • Presence of Local Players


Competitive Landscape:

Some of the key players profiled in the report are Teva Pharmaceutical Industries, Ltd. (Israel), Dr. Reddy’s Laboratories (India), Sandoz International GmbH (Germany), Apotex, Inc. (Canada), Par Pharmaceutical, Inc. (United States), Hospira, Inc. (United States), Watson Pharmaceuticals, Ltd. (India), Novartis (Switzerland), Fresenius SE & Co. KGaA (Germany), Pfizer (United States), Sun Pharmaceutical Industries (India), Ranbaxy Laboratories, Ltd (India), Actavis (Ireland), Mylan, Inc. (United States), Cipla (India) and Amneal Pharmaceuticals (United States). Additionally, following companies can also be profiled that are part of our coverage like Aurobindo Pharma Limited (India), Aspen Pharmacare Holdings Limited (South Africa), Lupin Limited (India) and Zydus Cadila (India). Analyst at AdvanceMarketAnalytics see United States, Europe, China and Indian Players to retain maximum share of Global Generic Drugs market by 2025. Considering Market by Sales Channel, the sub-segment i.e. Sales Channel Hospital Pharmacies will boost the Generic Drugs market. Considering Market by Drug Delivery, the sub-segment i.e. Oral will boost the Generic Drugs market.

In May 2020, Jubilant Generics Ltd entered into a non-exclusive licencing agreement with US-based Gilead Sciences Inc to manufacture and sell the potential COVID-19 drug Remdesivir in 127 countries.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Generic Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Generic Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Generic Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Simple Generic Drugs
  • Super Generic Drugs
  • Biosimilars
By Application
  • Respiratory Products
  • Anti-Infective Drugs
  • Central Nervous System Drugs
  • Cardiovascular Products
  • Anti-Arthritis Drugs
  • Anti-Cancer Drugs
  • Other
By Sales Channel
  • Sales Channel Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Channels

By Drug Delivery
  • Oral
  • Injectables
  • Dermal/Topical
  • Inhalers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Generic Drugs in Emerging Countries such as China and India
      • 3.2.2. Cost-Benefit compared to the Branded Drugs
      • 3.2.3. Large Number of Patent Expired Branded Drugs
    • 3.3. Market Challenges
      • 3.3.1. Presence of Local Players
    • 3.4. Market Trends
      • 3.4.1. Advent of Robotic Process Automation (RPA)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Generic Drugs, by Type, Application, Sales Channel, Drug Delivery and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Generic Drugs (Value)
      • 5.2.1. Global Generic Drugs by: Type (Value)
        • 5.2.1.1. Simple Generic Drugs
        • 5.2.1.2. Super Generic Drugs
        • 5.2.1.3. Biosimilars
      • 5.2.2. Global Generic Drugs by: Application (Value)
        • 5.2.2.1. Respiratory Products
        • 5.2.2.2. Anti-Infective Drugs
        • 5.2.2.3. Central Nervous System Drugs
        • 5.2.2.4. Cardiovascular Products
        • 5.2.2.5. Anti-Arthritis Drugs
        • 5.2.2.6. Anti-Cancer Drugs
        • 5.2.2.7. Other
      • 5.2.3. Global Generic Drugs by: Sales Channel (Value)
        • 5.2.3.1. Sales Channel Hospital Pharmacies
        • 5.2.3.2. Drug Stores
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Online Channels
      • 5.2.4. Global Generic Drugs by: Drug Delivery (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Injectables
        • 5.2.4.3. Dermal/Topical
        • 5.2.4.4. Inhalers
      • 5.2.5. Global Generic Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Generic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries, Ltd. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Dr. Reddy’s Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sandoz International GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Apotex, Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Par Pharmaceutical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hospira, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Watson Pharmaceuticals, Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fresenius SE & Co. KGaA (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sun Pharmaceutical Industries (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Ranbaxy Laboratories, Ltd (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Actavis (Ireland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Mylan, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Cipla (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Amneal Pharmaceuticals (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Generic Drugs Sale, by Type, Application, Sales Channel, Drug Delivery and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Generic Drugs (Value)
      • 7.2.1. Global Generic Drugs by: Type (Value)
        • 7.2.1.1. Simple Generic Drugs
        • 7.2.1.2. Super Generic Drugs
        • 7.2.1.3. Biosimilars
      • 7.2.2. Global Generic Drugs by: Application (Value)
        • 7.2.2.1. Respiratory Products
        • 7.2.2.2. Anti-Infective Drugs
        • 7.2.2.3. Central Nervous System Drugs
        • 7.2.2.4. Cardiovascular Products
        • 7.2.2.5. Anti-Arthritis Drugs
        • 7.2.2.6. Anti-Cancer Drugs
        • 7.2.2.7. Other
      • 7.2.3. Global Generic Drugs by: Sales Channel (Value)
        • 7.2.3.1. Sales Channel Hospital Pharmacies
        • 7.2.3.2. Drug Stores
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Online Channels
      • 7.2.4. Global Generic Drugs by: Drug Delivery (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Injectables
        • 7.2.4.3. Dermal/Topical
        • 7.2.4.4. Inhalers
      • 7.2.5. Global Generic Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Generic Drugs: by Type(USD Million)
  • Table 2. Generic Drugs Simple Generic Drugs , by Region USD Million (2014-2019)
  • Table 3. Generic Drugs Super Generic Drugs , by Region USD Million (2014-2019)
  • Table 4. Generic Drugs Biosimilars , by Region USD Million (2014-2019)
  • Table 5. Generic Drugs: by Application(USD Million)
  • Table 6. Generic Drugs Respiratory Products , by Region USD Million (2014-2019)
  • Table 7. Generic Drugs Anti-Infective Drugs , by Region USD Million (2014-2019)
  • Table 8. Generic Drugs Central Nervous System Drugs , by Region USD Million (2014-2019)
  • Table 9. Generic Drugs Cardiovascular Products , by Region USD Million (2014-2019)
  • Table 10. Generic Drugs Anti-Arthritis Drugs , by Region USD Million (2014-2019)
  • Table 11. Generic Drugs Anti-Cancer Drugs , by Region USD Million (2014-2019)
  • Table 12. Generic Drugs Other , by Region USD Million (2014-2019)
  • Table 13. Generic Drugs: by Sales Channel(USD Million)
  • Table 14. Generic Drugs Sales Channel Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 15. Generic Drugs Drug Stores , by Region USD Million (2014-2019)
  • Table 16. Generic Drugs Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 17. Generic Drugs Online Channels , by Region USD Million (2014-2019)
  • Table 18. Generic Drugs: by Drug Delivery(USD Million)
  • Table 19. Generic Drugs Oral , by Region USD Million (2014-2019)
  • Table 20. Generic Drugs Injectables , by Region USD Million (2014-2019)
  • Table 21. Generic Drugs Dermal/Topical , by Region USD Million (2014-2019)
  • Table 22. Generic Drugs Inhalers , by Region USD Million (2014-2019)
  • Table 23. South America Generic Drugs, by Country USD Million (2014-2019)
  • Table 24. South America Generic Drugs, by Type USD Million (2014-2019)
  • Table 25. South America Generic Drugs, by Application USD Million (2014-2019)
  • Table 26. South America Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 27. South America Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 28. Brazil Generic Drugs, by Type USD Million (2014-2019)
  • Table 29. Brazil Generic Drugs, by Application USD Million (2014-2019)
  • Table 30. Brazil Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 31. Brazil Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 32. Argentina Generic Drugs, by Type USD Million (2014-2019)
  • Table 33. Argentina Generic Drugs, by Application USD Million (2014-2019)
  • Table 34. Argentina Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 35. Argentina Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 36. Rest of South America Generic Drugs, by Type USD Million (2014-2019)
  • Table 37. Rest of South America Generic Drugs, by Application USD Million (2014-2019)
  • Table 38. Rest of South America Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 39. Rest of South America Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 40. Asia Pacific Generic Drugs, by Country USD Million (2014-2019)
  • Table 41. Asia Pacific Generic Drugs, by Type USD Million (2014-2019)
  • Table 42. Asia Pacific Generic Drugs, by Application USD Million (2014-2019)
  • Table 43. Asia Pacific Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 44. Asia Pacific Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 45. China Generic Drugs, by Type USD Million (2014-2019)
  • Table 46. China Generic Drugs, by Application USD Million (2014-2019)
  • Table 47. China Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 48. China Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 49. Japan Generic Drugs, by Type USD Million (2014-2019)
  • Table 50. Japan Generic Drugs, by Application USD Million (2014-2019)
  • Table 51. Japan Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 52. Japan Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 53. India Generic Drugs, by Type USD Million (2014-2019)
  • Table 54. India Generic Drugs, by Application USD Million (2014-2019)
  • Table 55. India Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 56. India Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 57. South Korea Generic Drugs, by Type USD Million (2014-2019)
  • Table 58. South Korea Generic Drugs, by Application USD Million (2014-2019)
  • Table 59. South Korea Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 60. South Korea Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 61. Taiwan Generic Drugs, by Type USD Million (2014-2019)
  • Table 62. Taiwan Generic Drugs, by Application USD Million (2014-2019)
  • Table 63. Taiwan Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 64. Taiwan Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 65. Australia Generic Drugs, by Type USD Million (2014-2019)
  • Table 66. Australia Generic Drugs, by Application USD Million (2014-2019)
  • Table 67. Australia Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 68. Australia Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Generic Drugs, by Type USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Generic Drugs, by Application USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 72. Rest of Asia-Pacific Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 73. Europe Generic Drugs, by Country USD Million (2014-2019)
  • Table 74. Europe Generic Drugs, by Type USD Million (2014-2019)
  • Table 75. Europe Generic Drugs, by Application USD Million (2014-2019)
  • Table 76. Europe Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 77. Europe Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 78. Germany Generic Drugs, by Type USD Million (2014-2019)
  • Table 79. Germany Generic Drugs, by Application USD Million (2014-2019)
  • Table 80. Germany Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 81. Germany Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 82. France Generic Drugs, by Type USD Million (2014-2019)
  • Table 83. France Generic Drugs, by Application USD Million (2014-2019)
  • Table 84. France Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 85. France Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 86. Italy Generic Drugs, by Type USD Million (2014-2019)
  • Table 87. Italy Generic Drugs, by Application USD Million (2014-2019)
  • Table 88. Italy Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 89. Italy Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 90. United Kingdom Generic Drugs, by Type USD Million (2014-2019)
  • Table 91. United Kingdom Generic Drugs, by Application USD Million (2014-2019)
  • Table 92. United Kingdom Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 93. United Kingdom Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 94. Netherlands Generic Drugs, by Type USD Million (2014-2019)
  • Table 95. Netherlands Generic Drugs, by Application USD Million (2014-2019)
  • Table 96. Netherlands Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 97. Netherlands Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 98. Rest of Europe Generic Drugs, by Type USD Million (2014-2019)
  • Table 99. Rest of Europe Generic Drugs, by Application USD Million (2014-2019)
  • Table 100. Rest of Europe Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 101. Rest of Europe Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 102. MEA Generic Drugs, by Country USD Million (2014-2019)
  • Table 103. MEA Generic Drugs, by Type USD Million (2014-2019)
  • Table 104. MEA Generic Drugs, by Application USD Million (2014-2019)
  • Table 105. MEA Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 106. MEA Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 107. Middle East Generic Drugs, by Type USD Million (2014-2019)
  • Table 108. Middle East Generic Drugs, by Application USD Million (2014-2019)
  • Table 109. Middle East Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 110. Middle East Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 111. Africa Generic Drugs, by Type USD Million (2014-2019)
  • Table 112. Africa Generic Drugs, by Application USD Million (2014-2019)
  • Table 113. Africa Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 114. Africa Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 115. North America Generic Drugs, by Country USD Million (2014-2019)
  • Table 116. North America Generic Drugs, by Type USD Million (2014-2019)
  • Table 117. North America Generic Drugs, by Application USD Million (2014-2019)
  • Table 118. North America Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 119. North America Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 120. United States Generic Drugs, by Type USD Million (2014-2019)
  • Table 121. United States Generic Drugs, by Application USD Million (2014-2019)
  • Table 122. United States Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 123. United States Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 124. Canada Generic Drugs, by Type USD Million (2014-2019)
  • Table 125. Canada Generic Drugs, by Application USD Million (2014-2019)
  • Table 126. Canada Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 127. Canada Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 128. Mexico Generic Drugs, by Type USD Million (2014-2019)
  • Table 129. Mexico Generic Drugs, by Application USD Million (2014-2019)
  • Table 130. Mexico Generic Drugs, by Sales Channel USD Million (2014-2019)
  • Table 131. Mexico Generic Drugs, by Drug Delivery USD Million (2014-2019)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Generic Drugs: by Type(USD Million)
  • Table 149. Generic Drugs Simple Generic Drugs , by Region USD Million (2020-2025)
  • Table 150. Generic Drugs Super Generic Drugs , by Region USD Million (2020-2025)
  • Table 151. Generic Drugs Biosimilars , by Region USD Million (2020-2025)
  • Table 152. Generic Drugs: by Application(USD Million)
  • Table 153. Generic Drugs Respiratory Products , by Region USD Million (2020-2025)
  • Table 154. Generic Drugs Anti-Infective Drugs , by Region USD Million (2020-2025)
  • Table 155. Generic Drugs Central Nervous System Drugs , by Region USD Million (2020-2025)
  • Table 156. Generic Drugs Cardiovascular Products , by Region USD Million (2020-2025)
  • Table 157. Generic Drugs Anti-Arthritis Drugs , by Region USD Million (2020-2025)
  • Table 158. Generic Drugs Anti-Cancer Drugs , by Region USD Million (2020-2025)
  • Table 159. Generic Drugs Other , by Region USD Million (2020-2025)
  • Table 160. Generic Drugs: by Sales Channel(USD Million)
  • Table 161. Generic Drugs Sales Channel Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 162. Generic Drugs Drug Stores , by Region USD Million (2020-2025)
  • Table 163. Generic Drugs Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 164. Generic Drugs Online Channels , by Region USD Million (2020-2025)
  • Table 165. Generic Drugs: by Drug Delivery(USD Million)
  • Table 166. Generic Drugs Oral , by Region USD Million (2020-2025)
  • Table 167. Generic Drugs Injectables , by Region USD Million (2020-2025)
  • Table 168. Generic Drugs Dermal/Topical , by Region USD Million (2020-2025)
  • Table 169. Generic Drugs Inhalers , by Region USD Million (2020-2025)
  • Table 170. South America Generic Drugs, by Country USD Million (2020-2025)
  • Table 171. South America Generic Drugs, by Type USD Million (2020-2025)
  • Table 172. South America Generic Drugs, by Application USD Million (2020-2025)
  • Table 173. South America Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 174. South America Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 175. Brazil Generic Drugs, by Type USD Million (2020-2025)
  • Table 176. Brazil Generic Drugs, by Application USD Million (2020-2025)
  • Table 177. Brazil Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 178. Brazil Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 179. Argentina Generic Drugs, by Type USD Million (2020-2025)
  • Table 180. Argentina Generic Drugs, by Application USD Million (2020-2025)
  • Table 181. Argentina Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 182. Argentina Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 183. Rest of South America Generic Drugs, by Type USD Million (2020-2025)
  • Table 184. Rest of South America Generic Drugs, by Application USD Million (2020-2025)
  • Table 185. Rest of South America Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 186. Rest of South America Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 187. Asia Pacific Generic Drugs, by Country USD Million (2020-2025)
  • Table 188. Asia Pacific Generic Drugs, by Type USD Million (2020-2025)
  • Table 189. Asia Pacific Generic Drugs, by Application USD Million (2020-2025)
  • Table 190. Asia Pacific Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 191. Asia Pacific Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 192. China Generic Drugs, by Type USD Million (2020-2025)
  • Table 193. China Generic Drugs, by Application USD Million (2020-2025)
  • Table 194. China Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 195. China Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 196. Japan Generic Drugs, by Type USD Million (2020-2025)
  • Table 197. Japan Generic Drugs, by Application USD Million (2020-2025)
  • Table 198. Japan Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 199. Japan Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 200. India Generic Drugs, by Type USD Million (2020-2025)
  • Table 201. India Generic Drugs, by Application USD Million (2020-2025)
  • Table 202. India Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 203. India Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 204. South Korea Generic Drugs, by Type USD Million (2020-2025)
  • Table 205. South Korea Generic Drugs, by Application USD Million (2020-2025)
  • Table 206. South Korea Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 207. South Korea Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 208. Taiwan Generic Drugs, by Type USD Million (2020-2025)
  • Table 209. Taiwan Generic Drugs, by Application USD Million (2020-2025)
  • Table 210. Taiwan Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 211. Taiwan Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 212. Australia Generic Drugs, by Type USD Million (2020-2025)
  • Table 213. Australia Generic Drugs, by Application USD Million (2020-2025)
  • Table 214. Australia Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 215. Australia Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 216. Rest of Asia-Pacific Generic Drugs, by Type USD Million (2020-2025)
  • Table 217. Rest of Asia-Pacific Generic Drugs, by Application USD Million (2020-2025)
  • Table 218. Rest of Asia-Pacific Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 219. Rest of Asia-Pacific Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 220. Europe Generic Drugs, by Country USD Million (2020-2025)
  • Table 221. Europe Generic Drugs, by Type USD Million (2020-2025)
  • Table 222. Europe Generic Drugs, by Application USD Million (2020-2025)
  • Table 223. Europe Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 224. Europe Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 225. Germany Generic Drugs, by Type USD Million (2020-2025)
  • Table 226. Germany Generic Drugs, by Application USD Million (2020-2025)
  • Table 227. Germany Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 228. Germany Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 229. France Generic Drugs, by Type USD Million (2020-2025)
  • Table 230. France Generic Drugs, by Application USD Million (2020-2025)
  • Table 231. France Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 232. France Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 233. Italy Generic Drugs, by Type USD Million (2020-2025)
  • Table 234. Italy Generic Drugs, by Application USD Million (2020-2025)
  • Table 235. Italy Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 236. Italy Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 237. United Kingdom Generic Drugs, by Type USD Million (2020-2025)
  • Table 238. United Kingdom Generic Drugs, by Application USD Million (2020-2025)
  • Table 239. United Kingdom Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 240. United Kingdom Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 241. Netherlands Generic Drugs, by Type USD Million (2020-2025)
  • Table 242. Netherlands Generic Drugs, by Application USD Million (2020-2025)
  • Table 243. Netherlands Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 244. Netherlands Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 245. Rest of Europe Generic Drugs, by Type USD Million (2020-2025)
  • Table 246. Rest of Europe Generic Drugs, by Application USD Million (2020-2025)
  • Table 247. Rest of Europe Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 248. Rest of Europe Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 249. MEA Generic Drugs, by Country USD Million (2020-2025)
  • Table 250. MEA Generic Drugs, by Type USD Million (2020-2025)
  • Table 251. MEA Generic Drugs, by Application USD Million (2020-2025)
  • Table 252. MEA Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 253. MEA Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 254. Middle East Generic Drugs, by Type USD Million (2020-2025)
  • Table 255. Middle East Generic Drugs, by Application USD Million (2020-2025)
  • Table 256. Middle East Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 257. Middle East Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 258. Africa Generic Drugs, by Type USD Million (2020-2025)
  • Table 259. Africa Generic Drugs, by Application USD Million (2020-2025)
  • Table 260. Africa Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 261. Africa Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 262. North America Generic Drugs, by Country USD Million (2020-2025)
  • Table 263. North America Generic Drugs, by Type USD Million (2020-2025)
  • Table 264. North America Generic Drugs, by Application USD Million (2020-2025)
  • Table 265. North America Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 266. North America Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 267. United States Generic Drugs, by Type USD Million (2020-2025)
  • Table 268. United States Generic Drugs, by Application USD Million (2020-2025)
  • Table 269. United States Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 270. United States Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 271. Canada Generic Drugs, by Type USD Million (2020-2025)
  • Table 272. Canada Generic Drugs, by Application USD Million (2020-2025)
  • Table 273. Canada Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 274. Canada Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 275. Mexico Generic Drugs, by Type USD Million (2020-2025)
  • Table 276. Mexico Generic Drugs, by Application USD Million (2020-2025)
  • Table 277. Mexico Generic Drugs, by Sales Channel USD Million (2020-2025)
  • Table 278. Mexico Generic Drugs, by Drug Delivery USD Million (2020-2025)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Generic Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Generic Drugs: by Application USD Million (2014-2019)
  • Figure 6. Global Generic Drugs: by Sales Channel USD Million (2014-2019)
  • Figure 7. Global Generic Drugs: by Drug Delivery USD Million (2014-2019)
  • Figure 8. South America Generic Drugs Share (%), by Country
  • Figure 9. Asia Pacific Generic Drugs Share (%), by Country
  • Figure 10. Europe Generic Drugs Share (%), by Country
  • Figure 11. MEA Generic Drugs Share (%), by Country
  • Figure 12. North America Generic Drugs Share (%), by Country
  • Figure 13. Global Generic Drugs share by Players 2019 (%)
  • Figure 14. Global Generic Drugs share by Players (Top 3) 2019(%)
  • Figure 15. Global Generic Drugs share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva Pharmaceutical Industries, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva Pharmaceutical Industries, Ltd. (Israel) Revenue: by Geography 2019
  • Figure 19. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 20. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2019
  • Figure 21. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Sandoz International GmbH (Germany) Revenue: by Geography 2019
  • Figure 23. Apotex, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Apotex, Inc. (Canada) Revenue: by Geography 2019
  • Figure 25. Par Pharmaceutical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Par Pharmaceutical, Inc. (United States) Revenue: by Geography 2019
  • Figure 27. Hospira, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Hospira, Inc. (United States) Revenue: by Geography 2019
  • Figure 29. Watson Pharmaceuticals, Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Watson Pharmaceuticals, Ltd. (India) Revenue: by Geography 2019
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 33. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2019
  • Figure 35. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United States) Revenue: by Geography 2019
  • Figure 37. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 38. Sun Pharmaceutical Industries (India) Revenue: by Geography 2019
  • Figure 39. Ranbaxy Laboratories, Ltd (India) Revenue, Net Income and Gross profit
  • Figure 40. Ranbaxy Laboratories, Ltd (India) Revenue: by Geography 2019
  • Figure 41. Actavis (Ireland) Revenue, Net Income and Gross profit
  • Figure 42. Actavis (Ireland) Revenue: by Geography 2019
  • Figure 43. Mylan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Mylan, Inc. (United States) Revenue: by Geography 2019
  • Figure 45. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 46. Cipla (India) Revenue: by Geography 2019
  • Figure 47. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 48. Amneal Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 49. Global Generic Drugs: by Type USD Million (2020-2025)
  • Figure 50. Global Generic Drugs: by Application USD Million (2020-2025)
  • Figure 51. Global Generic Drugs: by Sales Channel USD Million (2020-2025)
  • Figure 52. Global Generic Drugs: by Drug Delivery USD Million (2020-2025)
  • Figure 53. South America Generic Drugs Share (%), by Country
  • Figure 54. Asia Pacific Generic Drugs Share (%), by Country
  • Figure 55. Europe Generic Drugs Share (%), by Country
  • Figure 56. MEA Generic Drugs Share (%), by Country
  • Figure 57. North America Generic Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceutical Industries, Ltd. (Israel)
  • Dr. Reddy’s Laboratories (India)
  • Sandoz International GmbH (Germany)
  • Apotex, Inc. (Canada)
  • Par Pharmaceutical, Inc. (United States)
  • Hospira, Inc. (United States)
  • Watson Pharmaceuticals, Ltd. (India)
  • Novartis (Switzerland)
  • Fresenius SE & Co. KGaA (Germany)
  • Pfizer (United States)
  • Sun Pharmaceutical Industries (India)
  • Ranbaxy Laboratories, Ltd (India)
  • Actavis (Ireland)
  • Mylan, Inc. (United States)
  • Cipla (India)
  • Amneal Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Aurobindo Pharma Limited (India) , Aspen Pharmacare Holdings Limited (South Africa) , Lupin Limited (India) , Zydus Cadila (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation